
Sarepta Therapeutics Inc SRPT.O:
FDA INFORMS SAREPTA THAT IT RECOMMENDS THAT SAREPTA REMOVE ITS PAUSE AND RESUME SHIPMENTS OF ELEVIDYS FOR AMBULATORY INDIVIDUALS WITH DUCHENNE MUSCULAR DYSTROPHY
SAREPTA THERAPEUTICS INC - SHIPMENTS TO RESUME IMMINENTLY
SAREPTA THERAPEUTICS: CO AND FDA WILL CONTINUE DIALOGUE ON NEXT STEPS IN THE SAFETY LABELING PROCESS FOR ELEVIDYS